Clene Inc.

This clinical-stage pharmaceutical company develops clean-surfaced nanotechnology therapeutics designed to treat neurodegenerative diseases and central nervous system disorders, including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease. Its proprietary platform synthesizes stable, highly catalytic nanocrystals from transition elements without toxic organic residues. The company's lead drug asset is an orally administered gold nanocrystal suspension engineered to restore cellular energy metabolism, increase intracellular adenosine triphosphate production, and reduce oxidative stress and toxic protein aggregates. Additional pipeline candidates in early development include ionic solutions for infectious diseases and wound healing. It also markets mineral dietary supplements, either directly through a subsidiary or via licensing partnerships with supplement distributors.

The company operates its clinical research programs across various healthcare centers within the United States and has conducted long-term clinical trial extensions in Australia. In addition to its clinical pipeline, the company distributes commercial dietary supplements internationally through a licensing partner. The company's corporate headquarters and executive offices are not stated in the provided text.

Summary of the business section of Clene's latest annual report, written by StockData.

“As of December 31, 2025, we had a total of 79 employees, 76 of which were full-time and 3 were part-time, primarily located in Utah and Maryland.”